Covid-19 roundup: Pfiz­er/BioN­Tech spell out PhI­II pri­or­i­ty; Le­gal ex­perts urge FDA to re­frain from vac­cine EUAs

Milder side ef­fects among the el­der­ly were crit­i­cal in Pfiz­er and BioN­Tech’s choice of vac­cine can­di­date to send in­to Phase III test­ing, the com­pa­nies re­vealed in a preprint.

The Ger­man biotech dis­tin­guished its Covid-19 pro­gram right from the be­gin­ning by eval­u­at­ing four dif­fer­ent mR­NA con­structs. BNT162b1 and BNT162b2, two nu­cle­o­side-mod­i­fied RNAs for­mu­lat­ed in lipid nanopar­ti­cles, showed the most promis­ing re­sults in an­i­mal stud­ies and re­ceived fast track sta­tus in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER